Corticosteroids as Antiangiogenic Agents

Ophthalmology Clinics of North America

Volumn 19, Issue 3, 2006, Pages 345-351

  Oliver, Alejandro ^a   Ciulla, Thomas A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MIDWEST EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; GANCICLOVIR; POLYMER; PREDNISOLONE; SQUALAMINE; TRIAMCINOLONE; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; BIODEGRADABLE IMPLANT; CATARACT; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CORNEA NEOVASCULARIZATION; CORTICOSTEROID THERAPY; DIABETIC RETINOPATHY; DISEASE EXACERBATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; ENDOPHTHALMITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LASER COAGULATION; MACROPHAGE ACTIVATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OCULAR HISTOPLASMOSIS; OCULAR HISTOPLASMOSIS SYNDROME; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PSEUDOENDOPHTHALMITIS; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS; RETROLENTAL FIBROPLASIA; REVIEW; SUBRETINAL NEOVASCULARIZATION; SYNDROME; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; CORNEAL NEOVASCULARIZATION; DRUG ADMINISTRATION ROUTES; GLUCOCORTICOIDS; HUMANS; RETINAL NEOVASCULARIZATION; TREATMENT OUTCOME;

EID: 33747750921     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ohc.2006.05.002     Document Type: Review

References (52)

1. Crum R., Szabo S., and Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230 (1985) 1375-1378
2. Penfold P.L., Gyory J.F., Hunyor A.B., et al. Exudative macular degeneration and intravitreal triamcinolone: a pilot study. Aust N Z J Ophthalmol 23 (1995) 293-298
3. Challa J.K., Gillies M.C., Penfold P.L., et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 26 (1998) 277-281
4. Danis R.P., Ciulla T.A., Pratt L.M., et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20 (2000) 244-250
5. Ranson N.T., Danis R.P., Ciulla T.A., et al. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 86 (2002) 527-529
6. Martidis A., Miller D.G., Ciulla T.A., et al. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther 15 (1999) 425-428
7. Rechtman E., Allen V.D., Danis R.P., et al. Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 136 (2003) 739-741
8. Zein W.M., Noureddin B.N., Jurdi F.A., et al. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. Retina 26 (2006) 137-142
9. Makley T.A., Long J.W., and Suie T. Therapy of chorioretinitis presumed to be caused by histoplasmosis. Int Ophthalmol Clin 15 (1975) 181-196
10. Tokida Y., Aratani Y., Morita A., et al. Production of two variant laminin forms by endothelial cells and shift of their relative levels by angiostatic steroids. J Biol Chem 265 (1990) 1768-1775
11. Ingber D.E., Madri J.A., and Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 119 (1986) 1768-1775
12. Stokes C.L., Weisz P.B., Williams S.K., et al. Inhibition of microvascular endothelial cell migration by b-cyclodextrin tetradecasulfate and hydrocortisone. Microvasc Res 40 (1990) 279-284
13. Lee H., Baek S., Joe S.J., et al. Modulation of IFN-gamma production by TNF-alpha in macrophages from the tumor environment: significance as an angiogenic switch. Int Immunopharmacol 6 (2006) 71-78
14. Kodelja V., Muller C., Tenorio S., et al. Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology 197 (1997) 478-493
15. Matsuda S., Gomi F., Oshima Y., et al. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci 46 (2005) 1062-1068
16. Antoszyk A.N., Gottlieb J.L., Machemer R., et al. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 231 (1993) 34-40
17. Wang Y.S., Friedrichs U., Eichler W., et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 240 (2002) 42-48
18. Murata M., Shimizu S., Horiuchi S., et al. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 244 (2006) 205-209
19. Blei F., Wilson E.L., Mignatti P., et al. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 155 (1993) 568-578
20. Penn J.S., Rajaratnam V.S., Collier R.J., et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 42 (2001) 283-290
21. BenEzra D., Griffin B.W., Maftzir G., et al. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 38 (1997) 1954-1962
22. Clark A.F., Mellon J., Li X.Y., et al. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci 40 (1999) 2158-2162
23. Higgins R.D., Sanders R.J., Yan Y., et al. Squalamine improves retinal neovascularization. Invest Ophthalmol Vis Sci 41 (2000) 1507-1512
24. Genaidy M., Kazi A.A., Peyman G.A., et al. Effect of squalamine on iris neovascularization in monkeys. Retina 22 (2002) 772-778
25. Ciulla T.A., Criswell M.H., Danis R.P., et al. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 23 (2003) 808-814
26. Higgins R.D., Yan Y., Geng Y., et al. Regression of retinopathy by squalamine in a mouse model. Pediatr Res 56 (2004) 144-149
27. Ziada G., el-Haddad S., Fatouh M., et al. Radionuclide study of the blood ocular barrier. Eur J Drug Metab Pharmacokinet 10 (1985) 325-328
28. Jonas J.B., Kreissig I., and Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 87 (2003) 24-27
29. Sanborn G.E., Anand R., Torti R.E., et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch Ophthalmol 110 (1992) 188-195
30. Berger A.S., Cheng C.K., Pearson P.A., et al. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 37 (1996) 2318-2325
31. Haupert C.L., and Jaffe G.J. New and emerging treatments for patients with uveitis. Int Ophthalmol Clin 40 (2000) 205-220
32. Jaffe G., Pearson P.A., and Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina 20 (2000) 402-403
33. Shane T.S., and Martin D.F. Endopthalmitis-Gancioclovir Implant Study Group. Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 136 (2003) 649-654
34. Tan D.T., Chee S.P., Lim L., et al. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology 108 (2001) 2172-2181
35. Nozik R.A. Periocular injection of steroids. Trans Am Acad Ophthalmol Otolaryngol 76 (1972) 695-705
36. Giles C.L. Bulbar perforation during periocular injection of corticosteroids. Am J Ophthalmol 77 (1974) 438-441
37. Raab E.L. Limitation of motility after periocular corticosteroid injection. Am J Ophthalmol 78 (1974) 996-998
38. Gillies M.C., Simpson J.M., Luo W., et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121 (2003) 667-673
39. Spaide R., Sorenson J., and Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110 (2003) 1517-1525
40. Spaide R., Sorenson J., and Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetoinide for choroidal neovascularization. Ophthalmology 112 (2005) 301-304
41. Van de Moere A., Sandhu S.S., Kak R., et al. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology 112 (2005) 1896-1903
42. Freund K.B., Klais C.M., Eandi C.M., et al. Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol 124 (2006) 487-492
43. Augustin A.J., and Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113 (2006) 14-22
44. Augustin A.J., and Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 141 (2006) 638-645
45. Chan W.M., Lai T.Y., Wong A.L., et al. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 90 (2006) 337-341
46. Schlaegel T.F. Diagnosis and management of minimal recurrences of macular histoplasmosis. Int Ophthalmol Clin 15 (1975) 167-179
47. Ciulla T.A., Criswell M.H., Danis R.P., et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 119 (2001) 399-404
48. Tommila P., Summanen P., and Tervo T. Cortisone, heparin and argon laser in the treatment of corneal neovascularization. Acta Ophthalmol Suppl 182 (1987) 89-92
49. Cursiefen C., Wenkel H., Martus P., et al. Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 239 (2001) 514-521
50. Jonas J.B., Kreissig I., and Degenring R.F. Intravitreal triamcinolone acetonide as treatment of ischemic ophthalmopathy. Eur J Ophthalmol 13 (2003) 575-576
51. Degenring R.F., and Jonas J.B. Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization. Acta Ophthalmol Scand 83 (2005) 621
52. Nicolo M., Ghiglione D., Lai S., et al. Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 8 (2006)